PRESCRIPTION PATTERN IN OBESE AND NON-OBESE INFERTILE WOMEN WITH POLYCYSTIC OVARY SYNDROME IN A TERTIARY CARE HOSPITAL
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i3.22936Keywords:
Polycystic ovary syndrome, Overweight, Obese, Oral contraceptives, Clomiphene citrate, MetforminAbstract
 Objective: The objective of this study is to evaluate the treatment options for the management of obese and non-obese infertile women with polycystic ovary syndrome (PCOS).
Methods: A prospective observational study was conducted with 75 infertile PCOS women. The demographic details, body mass index, menstrual patterns, and current medication related to infertility were noted. The collected data were statistically represented in terms of range, frequency tables, and standard deviation wherever appropriate.
Results: A majority of the infertile PCOS women were aged 24–27 years with a mean age of 25.72±3.53 years, belonging to middle socioeconomic class (44%) and mostly found to be urban residents 68%. Most of the PCOS women were overweight (32%) and obese (21%) with irregular menstrual pattern (90.67%). In combination therapy, clomiphene citrate (CC) pre-treated with oral contraceptives (OC) (37.93%) was mostly given to obese PCOS patients followed by CC with metformin pre-administered with OC (31.03%), whilen on-obese PCOS patients were mostly administered CC with gonadotropins pre-treated with OC(44%). In single therapy, OC was mostly administered to both non-obese (90%) and obese PCOS patients (88.90%).
Conclusion: This study concluded that most of the infertile PCOS women were overweight and obese, a major risk actor causing hyperandrogenicity. CC pre-treated with OC and metformin with CC pre-treated with OC were mostly prescribed to obese PCOS patients. Lifestyle modifications along with treatment are strongly recommended, especially in obese PCOS patients.
Downloads
References
Teede H, Deeks A, Moran L. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010;8:41.
Mandrelle K, Kamath MS, Bondu DJ, Chandy A, Aleyamma T, George K, et al. Prevalence of metabolic syndrome in women with polycystic ovary syndrome attending an infertility clinic in a tertiary care hospital in south India. J Hum Reprod Sci 2012;5:26-31.
Ramanand SJ, Ghongane BB, Ramanand JB, Patwardhan MH, Ghanghas RR, Jain SS, et al. Clinical characteristics of polycystic ovary syndrome in Indian women. Indian J Endocrinol Metab 2013;17:138-45.
Rodin DA, Bano G, Bland JM, Taylor K, Nussey SS. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol (Oxf) 1998;49:91-9.
Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002;26:883-96.
Jyoti N, Jyoti K, Savita RS, Veena SG. Comparision of myo-inositol versus metformin on anthropometric parameters in Polycystic ovarian syndrome in women. Int J Pharm Pharm Sci 2017;9:144-8.
Shatha HA, Ali MA, AL-Musawi BJ. Serum irisin and leptin levels in obese and non-obese women with Polycystic ovary syndrome with reference to glucose homeostasis. Int J Pharm Pharm Sci 2016;8:276-83.
Vrunda D, Parul S, Rajal T, Kruti D. Study of 100 cases of Infertility in Polycystic ovarian syndrome and its management outcome. Int J Med Sci Public Health 2013;2:1041-5.
Surekha T, Himabindu Y, Sriharibabu M. Impact of socio-economic status on ovarian reserve markers. J Hum Reprod Sci 2013;6:201-4.
Sharon SM, Ricardo A, Teresa S, Calderon-Margalit R, Martha D, Catarina K, et al. Socioeconomic status and Polycystic Ovary Syndrome. J Womens Health 2011;20:413-9.
Dasgupta S, Reddy BM. The role of epistasis in the etiology of polycystic ovary syndrome among Indian women: SNP-SNP and SNP-environment interactions. Ann Hum Genet 2013;77:288-98.
Sarkar S, Das M, Mukhopadhyay B, Chakrabarti CS, Majumder PP. High prevalence of metabolic syndrome and its correlates in two tribal populations of India and the impact of urbanization. Indian J Med Res 2006;123:679-86.
Saxena P, Prakash A, Nigam A, Mishra A. Polycystic ovary syndrome: Is obesity a sine qua non? A clinical, hormonal, and metabolic assessment in relation to body mass index. Indian J Endocrinol Metab 2012;16:996-9.
Omokanye L, Ibiwoye-Jaiyeola O, Olatinwo A, Abdul I, Durowade K, Biliaminu S. Polycystic ovarian syndrome: Analysis of management outcomes among infertile women at a public health institution in Nigeria. Niger J Clin Pract 2015;13:44.
Orsino A, Van Eyk N, Hamilton J. Clinical features, investigations and management of adolescents with polycystic ovary syndrome. Paediatr Child Health 2005;10:602-8.
Kistner RW. Use of clomiphene citrate, HCG and HMG for induction of ovulation in human female. Fertil Steril 1966;17:569-83.
Dasari P, Pranahita G. The efficacy of metformin and clomiphene citrate combination compared with clomiphene citrate alone for ovulation induction in infertile patients with PCOS. J Hum Reprod Sci 2009;2:18-22.
Gill H, Tiwari P, Dabadghao P. Prevalence of polycystic ovary syndrome in young women from north India: A Community-based study. Indian J Endocrinol Metab 2012;16:S389-92.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
